142 related articles for article (PubMed ID: 27735042)
1. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment.
Barchetti F; Stagnitti A; Megna V; Al Ansari N; Marini A; Musio D; Monti ML; Barchetti G; Tombolini V; Catalano C; Panebianco V
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(18):3770-3776. PubMed ID: 27735042
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
3. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
Eiber M; Holzapfel K; Ganter C; Epple K; Metz S; Geinitz H; Kübler H; Gaa J; Rummeny EJ; Beer AJ
J Magn Reson Imaging; 2011 May; 33(5):1160-70. PubMed ID: 21509875
[TBL] [Abstract][Full Text] [Related]
4. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
[TBL] [Abstract][Full Text] [Related]
5. Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences.
Larbi A; Omoumi P; Pasoglou V; Michoux N; Triqueneaux P; Tombal B; Cyteval C; Lecouvet FE
Eur Radiol; 2019 Aug; 29(8):4503-4513. PubMed ID: 30413957
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
[TBL] [Abstract][Full Text] [Related]
7. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
8. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
Vadi SK; Singh B; Basher RK; Watts A; Sood AK; Lal A; Kakkar N; Singh SK
Clin Nucl Med; 2017 Aug; 42(8):e355-e361. PubMed ID: 28525448
[TBL] [Abstract][Full Text] [Related]
9. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
10. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of whole-body diffusion-weighted MRI (WB-DWI/MRI) in diagnosis, staging and follow-up of gastric cancer, in comparison to CT: a pilot study.
De Vuysere S; Vandecaveye V; De Bruecker Y; Carton S; Vermeiren K; Tollens T; De Keyzer F; Dresen RC
BMC Med Imaging; 2021 Feb; 21(1):18. PubMed ID: 33546626
[TBL] [Abstract][Full Text] [Related]
12. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.
Jacobs MA; Macura KJ; Zaheer A; Antonarakis ES; Stearns V; Wolff AC; Feiweier T; Kamel IR; Wahl RL; Pan L
Acad Radiol; 2018 Nov; 25(11):1405-1414. PubMed ID: 29627288
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.
Seemann MD; Meisetschlaeger G; Gaa J; Rummeny EJ
Eur J Med Res; 2006 Feb; 11(2):58-65. PubMed ID: 16504962
[TBL] [Abstract][Full Text] [Related]
15. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
[TBL] [Abstract][Full Text] [Related]
17. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors.
Carlbom L; Caballero-Corbalán J; Granberg D; Sörensen J; Eriksson B; Ahlström H
Ups J Med Sci; 2017 Mar; 122(1):43-50. PubMed ID: 27894208
[TBL] [Abstract][Full Text] [Related]
18. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a meta-analysis.
Li B; Li Q; Nie W; Liu S
Eur J Radiol; 2014 Feb; 83(2):338-44. PubMed ID: 24355655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
